JP2015512943A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015512943A5 JP2015512943A5 JP2015505921A JP2015505921A JP2015512943A5 JP 2015512943 A5 JP2015512943 A5 JP 2015512943A5 JP 2015505921 A JP2015505921 A JP 2015505921A JP 2015505921 A JP2015505921 A JP 2015505921A JP 2015512943 A5 JP2015512943 A5 JP 2015512943A5
- Authority
- JP
- Japan
- Prior art keywords
- compound according
- cancer
- group
- compound
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 20
- 210000004027 cell Anatomy 0.000 claims 10
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- 238000000034 method Methods 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 4
- 125000000217 alkyl group Chemical group 0.000 claims 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 4
- 201000002528 pancreatic cancer Diseases 0.000 claims 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 4
- 210000004881 tumor cell Anatomy 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 3
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 150000002367 halogens Chemical class 0.000 claims 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 2
- 150000002431 hydrogen Chemical class 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 230000005945 translocation Effects 0.000 claims 2
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000004565 tumor cell growth Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261623349P | 2012-04-12 | 2012-04-12 | |
| US61/623,349 | 2012-04-12 | ||
| PCT/US2013/036234 WO2013155341A1 (en) | 2012-04-12 | 2013-04-11 | Methods and compositions for treating ewings sarcoma family of tumors |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017080017A Division JP6345301B2 (ja) | 2012-04-12 | 2017-04-13 | ユーイング肉腫ファミリー腫瘍を治療するための方法及び組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015512943A JP2015512943A (ja) | 2015-04-30 |
| JP2015512943A5 true JP2015512943A5 (enExample) | 2017-02-23 |
| JP6130491B2 JP6130491B2 (ja) | 2017-05-17 |
Family
ID=49328171
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015505921A Active JP6130491B2 (ja) | 2012-04-12 | 2013-04-11 | ユーイング肉腫ファミリー腫瘍を治療するための方法及び組成物 |
| JP2017080017A Active JP6345301B2 (ja) | 2012-04-12 | 2017-04-13 | ユーイング肉腫ファミリー腫瘍を治療するための方法及び組成物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017080017A Active JP6345301B2 (ja) | 2012-04-12 | 2017-04-13 | ユーイング肉腫ファミリー腫瘍を治療するための方法及び組成物 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US9290449B2 (enExample) |
| EP (1) | EP2836481B1 (enExample) |
| JP (2) | JP6130491B2 (enExample) |
| KR (1) | KR102145835B1 (enExample) |
| CN (2) | CN107011242B (enExample) |
| AU (2) | AU2013245812B2 (enExample) |
| CA (1) | CA2869513C (enExample) |
| IL (1) | IL234993B (enExample) |
| IN (1) | IN2014DN09228A (enExample) |
| MX (1) | MX377618B (enExample) |
| NZ (2) | NZ700612A (enExample) |
| WO (1) | WO2013155341A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP3443750B2 (ja) | 1994-06-24 | 2003-09-08 | キョーラク株式会社 | ダボ付きパネル |
| US8232310B2 (en) | 2006-12-29 | 2012-07-31 | Georgetown University | Targeting of EWS-FLI1 as anti-tumor therapy |
| MX377618B (es) * | 2012-04-12 | 2025-03-07 | Univ Georgetown | Métodos y composiciones para el tratamiento de la familia de tumores del sarcoma de ewing. |
| MX2016004678A (es) * | 2013-10-24 | 2017-03-10 | Univ Georgetown | Composiciones para el tratamiento del cancer. |
| EP3204376B1 (en) | 2014-10-09 | 2023-04-19 | Oncternal Therapeutics, Inc. | Indolinone compounds and uses thereof |
| WO2016141161A1 (en) | 2015-03-03 | 2016-09-09 | Cureport, Inc. | Dual loaded liposomal pharmaceutical formulations |
| CN107530283A (zh) | 2015-03-03 | 2018-01-02 | 奎尔波特股份有限公司 | 组合脂质体药物制剂 |
| EP3436434B1 (en) * | 2016-03-31 | 2020-07-08 | Oncternal Therapeutics, Inc. | Indoline analogs and uses thereof |
| EP3490553B1 (en) | 2016-07-29 | 2024-08-28 | Oncternal Therapeutics, Inc. | Combination comprising an indolinone compound and its use in the treatment of lymphoma |
| EP3558266B1 (en) | 2016-12-21 | 2022-03-30 | The Board of Regents of The University of Texas System | Altertoxin ii as a selective inhibitor of ewing family of tumor cells |
| CN108186630B (zh) * | 2017-12-18 | 2020-07-31 | 温州医科大学 | 靛红类似物在制备抗肿瘤药物中的应用 |
| CN110870917B (zh) * | 2018-09-03 | 2022-03-15 | 上海市第一人民医院 | Ews或其上调剂在制备治疗糖尿病及防治糖尿病个体肿瘤发生的药物中的应用 |
| US12076310B2 (en) * | 2021-06-09 | 2024-09-03 | University Of Rochester | Compounds and methods for the treatment of acute myelogenous leukemia |
| CN114057626B (zh) * | 2021-12-07 | 2023-06-30 | 山东第一医科大学(山东省医学科学院) | 一种吲哚-2,3-二酮的衍生物和制备方法、抑制recql4特异性表达的抗肝癌药物 |
| US20250361227A1 (en) * | 2022-03-13 | 2025-11-27 | University Of Virginia Patent Foundation | Inhibitors of fli1 and erg |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU583793B2 (en) | 1983-07-22 | 1989-05-11 | Du Pont Pharmaceuticals Company | Phenylquinolinecarboxylic acids and derivatives as antitumor agents |
| EP1135123B1 (en) | 1998-12-04 | 2004-12-29 | Neurosearch A/S | Use of isatin derivatives as ion channel activating agents |
| CN1155572C (zh) | 2001-01-19 | 2004-06-30 | 中国人民解放军军事医学科学院毒物药物研究所 | 吲哚类衍生物及其抗肿瘤用途 |
| US20030157486A1 (en) | 2001-06-21 | 2003-08-21 | Graff Jonathan M. | Methods to identify signal sequences |
| CA2562151C (en) | 2004-04-30 | 2016-09-06 | Alnylam Pharmaceuticals, Inc. | Oligonucleotides comprising a c5-modified pyrimidine |
| AR056317A1 (es) | 2005-04-20 | 2007-10-03 | Xenon Pharmaceuticals Inc | Compuestos de oxindol y composicion farmaceutica |
| WO2006117414A1 (es) | 2005-04-29 | 2006-11-09 | Proyecto De Biomedicina Cima, S.L. | Modelo animal no humano de sarcoma |
| WO2008046083A2 (en) * | 2006-10-12 | 2008-04-17 | Xenon Pharmaceuticals Inc. | Use of oxindole compounds as therapeutic agents |
| US8232310B2 (en) | 2006-12-29 | 2012-07-31 | Georgetown University | Targeting of EWS-FLI1 as anti-tumor therapy |
| AU2007341977B2 (en) | 2006-12-29 | 2013-05-23 | Georgetown University | Targeting of EWS-FLI1 as anti-tumor therapy |
| CA2684594C (en) * | 2007-04-20 | 2015-10-06 | The Research Foundation Of State University Of New York | Benzimidazoles and pharmaceutical compositions thereof for treating mycobacterium tuberculosis or francisella tulerensis infection |
| US8377992B2 (en) * | 2007-10-22 | 2013-02-19 | The Wistar Institute | TRBD-binding effectors and methods for using the same to modulate telomerase activity |
| US8710068B2 (en) | 2009-01-19 | 2014-04-29 | The Trustees Of The University Of Pennsylvania | Method of treating cancer using a survivin inhibitor |
| WO2012078519A2 (en) | 2010-12-06 | 2012-06-14 | Numerate, Inc. | 3-acylidene-2-oxoindole derivatives for inhibition of transglutaminase 2 |
| MX377618B (es) | 2012-04-12 | 2025-03-07 | Univ Georgetown | Métodos y composiciones para el tratamiento de la familia de tumores del sarcoma de ewing. |
| CN103435606A (zh) | 2013-08-22 | 2013-12-11 | 中国药科大学 | CDK2与GSK3β双重抑制剂及用途 |
| MX2016004678A (es) | 2013-10-24 | 2017-03-10 | Univ Georgetown | Composiciones para el tratamiento del cancer. |
| EP3204376B1 (en) | 2014-10-09 | 2023-04-19 | Oncternal Therapeutics, Inc. | Indolinone compounds and uses thereof |
-
2013
- 2013-04-11 MX MX2014011583A patent/MX377618B/es active IP Right Grant
- 2013-04-11 NZ NZ700612A patent/NZ700612A/en unknown
- 2013-04-11 NZ NZ723971A patent/NZ723971A/en unknown
- 2013-04-11 CA CA2869513A patent/CA2869513C/en active Active
- 2013-04-11 WO PCT/US2013/036234 patent/WO2013155341A1/en not_active Ceased
- 2013-04-11 EP EP13776244.9A patent/EP2836481B1/en active Active
- 2013-04-11 AU AU2013245812A patent/AU2013245812B2/en active Active
- 2013-04-11 IN IN9228DEN2014 patent/IN2014DN09228A/en unknown
- 2013-04-11 CN CN201611030609.9A patent/CN107011242B/zh active Active
- 2013-04-11 KR KR1020147031650A patent/KR102145835B1/ko active Active
- 2013-04-11 US US14/388,671 patent/US9290449B2/en active Active
- 2013-04-11 JP JP2015505921A patent/JP6130491B2/ja active Active
- 2013-04-11 CN CN201380030414.2A patent/CN104395288B/zh active Active
-
2014
- 2014-10-05 IL IL234993A patent/IL234993B/en active IP Right Grant
-
2016
- 2016-02-10 US US15/040,840 patent/US9714222B2/en active Active
-
2017
- 2017-03-06 AU AU2017201507A patent/AU2017201507B2/en active Active
- 2017-04-13 JP JP2017080017A patent/JP6345301B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015512943A5 (enExample) | ||
| RU2015151502A (ru) | Химические соединения | |
| JP2013510120A5 (enExample) | ||
| RU2018138828A (ru) | Уменьшение массы опухоли путем введения ccr1 антагонистов в комбинации с pd-1 ингибиторами или pd-l1 ингибиторами | |
| JP2008535902A5 (enExample) | ||
| JP2016515561A5 (enExample) | ||
| JP2017509586A5 (enExample) | ||
| EA201201161A1 (ru) | Пирролопиримидины в качестве ингибиторов cdk4/6 | |
| MX2012013274A (es) | Novedosos derivados de la pirimidina. | |
| EA201591662A1 (ru) | Липиды и липидные композиции для доставки активных агентов | |
| JP2014500870A5 (enExample) | ||
| JP2013512263A5 (enExample) | ||
| JP2017511321A5 (enExample) | ||
| JP2014508752A5 (enExample) | ||
| RU2020102453A (ru) | Фармацевтические композиции | |
| JP2015520143A5 (enExample) | ||
| JP2017514910A5 (enExample) | ||
| BR112012027743A2 (pt) | ciclopropil dicarboxamidas e análogos exibindo atividades anticâncer e antiproliferativas | |
| RU2014115847A (ru) | Пирролопиримидиновые соединения для лечения злокачественной опухоли | |
| JP2015508103A5 (enExample) | ||
| JP2014508804A5 (enExample) | ||
| JP2012504628A5 (enExample) | ||
| JP2009530392A5 (enExample) | ||
| JP2017517565A5 (enExample) | ||
| EA201401082A1 (ru) | Фармацевтические препараты, содержащие антагонисты ccr3 |